相关实验视频

Updated: Jun 29, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K

新型疫苗的目标是针对I型的互白素-1受体

Yanzhao Zhou1, Jianwu Huang1, Wuqian Mai1

  • 1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Engineering Research Center for Immunological Diagnosis and Therapy of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

International immunopharmacology
|March 30, 2024
PubMed
概括

在小鼠模型中,针对类型I (IL-1R1) 的互白素-1受体治疗性疫苗有效降低了动脉样硬化和改善了心脏功能. 这些新型疫苗提供了一种有前途的预防策略,可以预防动脉样硬化和心肌梗塞等心血管疾病.

关键词:
这是一种抗炎症药物.动脉样硬化是一种动脉样硬化.一个IL-1受体.巨细胞是一个巨细胞.治疗性疫苗 治疗性疫苗

更多相关视频

Intralymphatic Immunotherapy and Vaccination in Mice07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.2K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Cross-reactivity00:42

Cross-reactivity

Overview
31.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137